Centers for Disease Control and Prevention Model Performance Evaluation Program Human Immunodeficiency Virus Type 1 (HIV-1)

Ribonucleic Acid (RNA) Determinations

Figures Used for the Analysis
of the
February 12, 2002 Performance Evaluation
Testing Results Reported by Participant Laboratories

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention
Public Health Practice Program Office
Division of Laboratory Systems
Atlanta, Georgia 30341-3717

Report of the February 12, 2002 Human Immunodeficiency Virus Type I (HIV-1) Ribonucleic Acid (RNA) Performance Evaluation Sample Testing Results Provided by Participant Laboratories in the Model Performance Evaluation Program, Centers for Disease Control and Prevention (CDC).

The production of this report was coordinated in CDC by:

Public Health Practice Program Office......Edward L. Baker, M.D., M.P.H., Director Division of Laboratory Systems......Robert Martin, Dr.P.H., DirectorThomas L. Hearn, Ph.D., Deputy Director

The material in this report was developed and prepared by:

Model Performance Evaluation Program (MPEP)......G. David, Cross, M.S., Acting Chief MPEP HIV-1 RNA Performance Evaluation......Michelle B. Kahn, M.S., D.V.M. HIV-1 RNA Project Coordinator

Information about this report should be addressed to the Model Performance Evaluation Program by calling (770) 488-8095 or (770) 488-8091.

Centers for Disease Control and Prevention (CDC) Model Performance Evaluation Program Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Testing February 12, 2002 Participant Laboratory Shipment

<u>Table 1.</u> Panel and Vial Designations, CDC Donor Numbers, CDC HIV-1 RNA Test Results, and Donor HIV Status

Panel Letter	Vial Label	CDC Donor Number	CDC Test Result ²	Donor HIV Status Test Res	Laboratory Interpretation ¹ and/or Results ult Interpretation
Α	A1, A5 A2 A3 A4	1 4 3 5	Positive Negative Ur Positive Negative	Infected ninfected Infected Uninfected	
В	B1 B2 B3, B4 B5	4 3 1 5	Negative Positive Positive Negative	Uninfected Infected Infected Uninfected	

Laboratory Interpretation space (to be completed by participant laboratory) provided to facilitate comparison of participant laboratory result with CDC result.

The CDC result was obtained after pre-shipment testing with three manufactured kits for determining the presence of HIV-1 RNA. Two of these kits are licensed by the Food and Drug Administration (FDA). The CDC result is consistent with the manufacturer-s criteria for interpretation of results.

Centers for Disease Control and Prevention (CDC) Model Performance Evaluation Program for Human Immunodeficiency Virus Type I (HIV-1) Ribonucleic Acid (RNA) Testing

<u>Table 2.</u> CDC HIV-1 RNA Testing Results for the February 12, 2002 Participant Laboratory Panel Samples

Panel Letter	Vial Label	CDC Donor Number	CDC Test Results ¹	Test Kit CI Manufacturer Interpr	
A	A1, A5	1	HIV RNA detected HIV RNA detected HIV RNA detected	Roche Amplicor HIV-1 Monitor J bioMeriéux NucliSens 7 HIV-1 QT Bayer 3.0 Quantitative Assay (bDNA)	Positive Positive Positive
	A2	4	No HIV RNA detected No HIV RNA detected No HIV RNA detected	Roche Amplicor HIV-1 MonitorJ bioMeriéux NucliSens7 HIV-1 QT Bayer 3.0 Quantitative Assay (bDNA)	Negative Negative Negative
	A3	3	HIV RNA detected HIV RNA detected HIV RNA detected	Roche Amplicor HIV-1MonitorJ bioMeriéux NucliSens7 HIV-1 QT Bayer 3.0 Quantitative Assay (bDNA)	Positive Positive Positive
	A4	5	No HIV RNA detected No HIV RNA detected No HIV RNA detected	Roche Amplicor HIV-1 Monitor J bioMeriéux NucliSens 7 HIV-1 QT Bayer 3.0 Quantitative Assay (bDNA)	Negative Negative Negative
В	B1	4	No HIV RNA detected No HIV RNA detected No HIV RNA detected	Roche Amplicor HIV-1 MonitorJ bioMeriéux NucliSens7 HIV-1 QT) Bayer 3.0 Quantitative Assay (bDNA)	Negative Negative Negative
	B2	3	HIV RNA detected HIV RNA detected HIV RNA detected	Roche Amplicor HIV-1 MonitorJ bioMeriéux NucliSens7 HIV-1 QT Bayer 3.0 Quantitative Assay (bDNA)	Positive Positive Positive
	B3, B4	1	HIV RNA detected HIV RNA detected HIV RNA detected	Roche Amplicor HIV-1 MonitorJ bioMeriéux NucliSens7 HIV-1 QT Bayer 3.0 Quantitative Assay (bDNA)	Positive Positive Positive
	В5	5	No HIV RNA detected No HIV RNA detected No HIV RNA detected	Roche Amplicor HIV-1 MonitorJ bioMeriéux NucliSens7 HIV-1 QT Bayer 3.0 Quantitative Assay (bDNA)	Negative Negative Negative


¹The CDC test results were obtained after pre-shipment testing with three manufactured kits for determining the presence of HIV-1 RNA. Two of these kits are licensed by the Food and Drug Administration (FDA).

²The CDC interpretation is consistent with the manufacturer's criteria for interpretation of results. Positive = HIV-1 RNA detected; Negative = HIV-1 RNA not detected (based on lower limit of test kit sensitivity).


SUPPLEMENTAL INFORMATION FOR COMPREHENDING THE NUMBERS USED TO LABEL FIGURES IN THIS REPORT

The "N=" that appears on each graph represents the number of laboratories that reported results. For some graphs, laboratories reported results using more than one test; therefore, the number of results may exceed the actual number of laboratories providing reports. The number appearing directly above or within each bar represents a frequency of results only.

Figure 1. Summary of Results Reported by Participant Laboratories for HIV-1 RNA Determinations in the February 12, 2002 Performance Evaluation Survey



Results of HIV-1 RNA Determinations Reported for the Three Samples Obtained From Two HIV-1 Infected Donors with Detectable HIV-1 RNA



Results of HIV-1 RNA Determinations Reported for the Two Samples
Obtained From Two Uninfected Donors

Figure 2. Types of Laboratories Performing HIV-1 RNA Determinations in the February 12, 2002 Performance Evaluation Survey




Figure 3. Types of Test Kits Used to Perform HIV-1 RNA Determinations in the February 12, 2002 Performance Evaluation Survey




Table 3. Results of the HIV-1 RNA Determinations Reported by Participant Laboratories for the February 12, 2002 Performance Evaluation Survey.

CDC Donor #1

Donor Status: HIV-1 Infected and HIV-1 RNA Detected

Panel Vial Labels: A1, B3

	No. of Results Detecting RNA	No. of Results Not Detecting RNA	_	of Results R	-
Test Kit			minimum	median	maximum
Roche Amplicor HIV-1 Monitor TM	122	3	314	1,258	7,117
Bayer HIV-1 RNA 3.0 Quantitive Assay (bDNA)	45	0	429	1,281	3,780
bioMeriéux NucliSens® HIV-1 QT	8	0	630	960	8,500
In House	1	0	3,400	3,400	3,400
Other	1	0	147	147	147

CDC Donor #1 (Duplicate)

Donor Status: HIV-1 Infected and HIV-1 RNA Detected

Panel Vial Labels: A5, B4

	No. of Results Detecting RNA	No. of Results Not Detecting RNA	_	of Results R	•
Test Kit			minimum	median	maximum
Roche Amplicor HIV-1 Monitor [™]	122	3	424	1,108	9,703
Bayer HIV-1 RNA 3.0 Quantitive Assay (bDNA)	45	0	587	1,240	3,712
bioMeriéux NucliSens® HIV-1 QT	8	0	655	950	1,700
In House	1	0	3,100	3,100	3,100
Other	1	0	158	158	158

Table 3. Results of the HIV-1 RNA Determinations Reported by Participant Laboratories for the February 12, 2002 Performance Evaluation Survey.

CDC Donor # 3

Donor Status: HIV-1 Infected and HIV-1 RNA Detected

Panel Vial Labels: A3, B2

	No. of Results Detecting RNA	No. of Results Not Detecting RNA		of Results R	•
Test Kit			minimum	median	maximum
Roche Amplicor HIV-1 Monitor [™]	125	0	3,417	13,396	52,591
Bayer HIV-1 RNA 3.0 Quantitive Assay (bDNA)	45	0	9,710	15,300	35,488
bioMeriéux NucliSens® HIV-1 QT	8	0	15,500	28,500	49,000
In House	1	0	39,000	39,000	39,000
Other	1	0	28,900	28,900	28,900

This Space Is Intentionally Left Blank

Table 3. Results of the HIV-1 RNA Determinations Reported by Participant Laboratories for the February 12, 2002 Performance Evaluation Survey.

CDC Donor #4

Donor Status: HIV-1 Uninfected Panel Vial Labels: A2, B1

	No. of Results Detecting RNA	No. of Results Not Detecting RNA	_	of Results R	-
Test Kit			minimum	median	maximum
Roche Amplicor HIV-1 Monitor TM	2	123	90	100	110
Bayer HIV-1 RNA 3.0 Quantitive Assay (bDNA)	0	45	<kit sens.*<="" td=""><td><kit sens.<="" td=""><td><kit sens.<="" td=""></kit></td></kit></td></kit>	<kit sens.<="" td=""><td><kit sens.<="" td=""></kit></td></kit>	<kit sens.<="" td=""></kit>
bioMeriéux NucliSens® HIV-1 QT	0	8	<kit sens.<="" td=""><td><kit sens.<="" td=""><td><kit sens.<="" td=""></kit></td></kit></td></kit>	<kit sens.<="" td=""><td><kit sens.<="" td=""></kit></td></kit>	<kit sens.<="" td=""></kit>
In House	0	1	<kit sens.<="" td=""><td><kit sens.<="" td=""><td><kit sens.<="" td=""></kit></td></kit></td></kit>	<kit sens.<="" td=""><td><kit sens.<="" td=""></kit></td></kit>	<kit sens.<="" td=""></kit>
Other	0	1	<kit sens.<="" td=""><td><kit sens.<="" td=""><td><kit sens.<="" td=""></kit></td></kit></td></kit>	<kit sens.<="" td=""><td><kit sens.<="" td=""></kit></td></kit>	<kit sens.<="" td=""></kit>

^{* =} less than kit lower limit sensitivity

CDC Donor #5

Donor Status: HIV-1 Uninfected Panel Vial Labels: A4, B5

	No. of Results Detecting RNA	No. of Results Not Detecting RNA	_	of Results R	•
Test Kit			minimum	median	maximum
Roche Amplicor HIV-1 Monitor TM	2	123	806	5,792	10,778
Bayer HIV-1 RNA 3.0 Quantitive Assay (bDNA)	1	44	196	196	196
bioMeriéux NucliSens® HIV-1 QT	0	8	<kit sens.*<="" td=""><td><kit sens.<="" td=""><td><kit sens.<="" td=""></kit></td></kit></td></kit>	<kit sens.<="" td=""><td><kit sens.<="" td=""></kit></td></kit>	<kit sens.<="" td=""></kit>
In House	0	1	<kit sens.<="" td=""><td><kit sens.<="" td=""><td><kit sens.<="" td=""></kit></td></kit></td></kit>	<kit sens.<="" td=""><td><kit sens.<="" td=""></kit></td></kit>	<kit sens.<="" td=""></kit>
Other	0	1	<kit sens.<="" td=""><td><kit sens.<="" td=""><td><kit sens.<="" td=""></kit></td></kit></td></kit>	<kit sens.<="" td=""><td><kit sens.<="" td=""></kit></td></kit>	<kit sens.<="" td=""></kit>

^{* =} less than kit lower limit sensitivity